AT-1007

AT-1007 is an investigational nanoparticle-based therapy being developed by Ahead Therapeutics for the treatment of rheumatoid arthritis. It utilizes a proprietary technology platform designed for in vivo immune reprogramming, which employs tolerogenic nanoparticles to induce antigen-specific immune tolerance. The mechanism involves mimicking the natural process of apoptotic cell clearance to deliver specific autoantigens to the immune system in a non-inflammatory context. This approach is intended to reprogram the immune system to stop its autoimmune attack on joint tissues without the need for broad, non-specific immunosuppression.